Compare FFIC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIC | CRVS |
|---|---|---|
| Founded | 1929 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.3M | 546.7M |
| IPO Year | 1995 | 2016 |
| Metric | FFIC | CRVS |
|---|---|---|
| Price | $15.03 | $6.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | 503.3K | ★ 1.7M |
| Earning Date | 01-27-2026 | 11-04-2025 |
| Dividend Yield | ★ 5.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $143,853,000.00 | N/A |
| Revenue This Year | $113.60 | N/A |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.65 | $2.54 |
| 52 Week High | $17.79 | $9.60 |
| Indicator | FFIC | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 36.31 |
| Support Level | $14.49 | $6.45 |
| Resistance Level | $15.46 | $7.18 |
| Average True Range (ATR) | 0.56 | 0.46 |
| MACD | -0.28 | -0.08 |
| Stochastic Oscillator | 24.44 | 20.06 |
Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).